QX Therapeutics, Inc.

New Haven, CT · Biotech · Private

MAP3K inhibitor therapeutics (repurposed pazopanib) for acute lung injury and acute respiratory distress syndrome

Grants
$297K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
2 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Small Molecules MAP3K2/3 Inhibitor for Treatment of Acute Lung Injury$296,641
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1241Lattice Automation, Inc——
1242Antag Therapeutics——
1243DEKK-TEC, INC.——
1244QX Therapeutics, Inc.——
1245DIGITAL PROTEOMICS LLC——
1246New England Discovery Partners, LLC——
1247TARGUT BIOTECHNOLOGIES INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 5

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.